{"id":"pla-panto-levoflox-azithro","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"QT prolongation (azithromycin)"},{"rate":null,"effect":"Tendinopathy (fluoroquinolone)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion. Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. Azithromycin is a macrolide antibiotic that binds to the bacterial 50S ribosomal subunit, inhibiting protein synthesis. Together, these agents provide acid suppression and broad-spectrum antimicrobial coverage.","oneSentence":"PLA is a triple-agent combination that reduces gastric acid (pantoprazole), inhibits bacterial DNA gyrase (levofloxacin), and suppresses protein synthesis (azithromycin) to treat infections and acid-related disorders.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:26:17.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"},{"name":"Acid-related gastrointestinal disorders with concurrent infection"}]},"trialDetails":[{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zoltum®, Truxa® (MTV SA, Argentina), Levofloxacino, AsoMex"],"phase":"phase_3","status":"active","brandName":"PLA (Panto+Levoflox+Azithro)","genericName":"PLA (Panto+Levoflox+Azithro)","companyName":"Asofarma de México S.A de C.V.","companyId":"asofarma-de-m-xico-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The PLA (Panto+Levoflox+Azithro) combination is a small molecule treatment modality for Helicobacter Pylori Gastritis. It is being studied as an alternative to CLA (Clarithro+Lanso+Amoxi) in clinical trials for Helicobacter Pylori eradication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}